menu
    • menu
    [{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Netupitant","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Esteve Quimica \/ Esteve Quimica","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Quimica \/ Esteve Quimica"},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Esteve Quimica \/ Acorda Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Quimica \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Mecasermin","moa":"Insulin-like growth factor I receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Huayi Pharmaceutical \/ Esteve Huayi Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Esteve Quimica

    Menu

    Esteve Quimica

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mecasermin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

                            Details : Under the licensing agfreement, Esteve will hold the rights of Increlex (mecasermin). It is being indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency.

                            Product Name : Increlex

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 01, 2025

                            Lead Product(s) : Mecasermin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Esteve Quimica

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Quimica

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Helsinn Group & ESTEVE Renew Partnership for AKYNZEO® and ALOXI® in Germany

                            Details : The agreement aims for the commercialization of Akynzeo (combination of netupitant-palonosetron) and Aloxi (palonosetron) for the treatment of chemotherapy-induced nausea and vomiting in adults.

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Esteve Quimica

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Quimica

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Acorda Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ESTEVE Launches INBRIJA® in Spain

                            Details : Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.

                            Product Name : Inbrija

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Acorda Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Acorda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Esteve Launches INBRIJA® in Germany

                            Details : INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibito...

                            Product Name : Inbrija

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 16, 2022

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Acorda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Acorda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

                            Details : Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.

                            Product Name : Inbrija

                            Product Type : Other Small Molecule

                            Upfront Cash : $5.6 million

                            September 11, 2021

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Acorda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Acorda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

                            Details : Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.

                            Product Name : Inbrija

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 22, 2021

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Acorda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Huayi Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Kowa Pharmaceuticals America

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Esteve and Kowa Pharmaceuticals America Enter into an Exclusive License and Commercialization Agreement for Ri...

                            Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 05, 2021

                            Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Kowa Pharmaceuticals America

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Esteve Quimica

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Esteve Quimica

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Premier Research Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III C...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2017

                            Lead Product(s) : Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Premier Research Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth